Journal article
Consensus Report of the 2021 National Cancer Institute Neuroendocrine Tumor Clinical Trials Planning Meeting
JNCI : Journal of the National Cancer Institute, Vol.115(9), pp.1001-1010
09/2023
DOI: 10.1093/jnci/djad096
PMCID: PMC10483264
PMID: 37255328
Abstract
Important progress has been made over the last decade in the classification, imaging, and treatment of neuroendocrine neoplasm (NENs) with several new agents approved for use. While the treatment options available for patients with well-differentiated NETs have greatly expanded, the rapidly changing landscape has presented several unanswered questions about how best to optimize, sequence, and individualize therapy. Perhaps the most important development over the last decade has been the approval of 177Lu-DOTATATE for treatment of GEP-NETs, raising questions around optimal sequencing of peptide receptor radionuclide therapy (PRRT) relative to other therapeutic options, the role of re-treatment with PRRT, and whether PRRT can be further optimized through use of dosimetry among other approaches. The NET Task Force of the National Cancer Institute GI Steering Committee convened a clinical trial planning meeting (CTPM) in 2021 with multidisciplinary experts from academia, the federal government, industry, and patient advocates to develop NET clinical trials in the era of PRRT. Key clinical trial recommendations for development included: 1) PRRT re-treatment; 2) PRRT and immunotherapy combinations; 3) PRRT and DNA damage repair inhibitor combinations; 4) Treatment for liver dominant disease; 5) Treatment for PRRT resistant disease; and 6) Dosimetry modified PRRT.
Details
- Title: Subtitle
- Consensus Report of the 2021 National Cancer Institute Neuroendocrine Tumor Clinical Trials Planning Meeting
- Creators
- Simron Singh - Sunnybrook Health Science CentreThomas A Hope - University of California, San FranciscoEmily B Bergsland - University of California, San FranciscoLisa Bodei - Memorial Sloan Kettering Cancer CenterDavid L Bushnell - University of IowaJennifer A Chan - Dana-Farber Cancer InstituteBeth R Chasen - The University of Texas MD Anderson Cancer CenterAman Chauhan - Sylvester Comprehensive Cancer CenterSatya Das - AstraZeneca (Brazil)Arvind Dasari - The University of Texas MD Anderson Cancer CenterJaydira Del Rivero - National Institutes of HealthGhassan El-Haddad - Moffitt Cancer CenterKaryn A Goodman - Icahn School of Medicine at Mount SinaiDaniel M Halperin - The University of Texas MD Anderson Cancer CenterMark A Lewis - Intermountain HealthcareO Wolf Lindwasser - National Cancer InstituteSten Myrehaug - Sunnybrook Health Science CentreNitya P Raj - Memorial Sloan Kettering Cancer CenterDiane L Reidy-Lagunes - Memorial Sloan Kettering Cancer CenterHeloisa P Soares - University of UtahJonathan R Strosberg - Moffitt Cancer CenterElise C Kohn - National Cancer InstitutePamela L Kunz - Yale UniversityNET CTPM participants
- Resource Type
- Journal article
- Publication Details
- JNCI : Journal of the National Cancer Institute, Vol.115(9), pp.1001-1010
- DOI
- 10.1093/jnci/djad096
- PMID
- 37255328
- PMCID
- PMC10483264
- NLM abbreviation
- J Natl Cancer Inst
- eISSN
- 1460-2105
- Grant note
- DOI: 10.13039/100000054, name: National Cancer Institute
- Language
- English
- Electronic publication date
- 05/31/2023
- Date published
- 09/2023
- Academic Unit
- Radiology
- Record Identifier
- 9984420933902771
Metrics
10 Record Views